As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > TRENDS
TRENDS
-
AG Shares Reach 50-60% in 1 Year; Confidence in Quality Encourages Dominance Even without Market Lead
November 30, 2015
-
Full-Year Forecasts for Domestic Market Down vs Previous Year; Major Makers Struggling Even in Year without NHI Price Revision
November 11, 2015
-
Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
October 30, 2015
-
Drug Makers’ Payments to Medical Institutions Dip for Second Year: Jiho Tally
September 15, 2015
-
Transformation of ARB Market Spurred by AGs, Power Map Changing Fast as Brand-Name Drugs Falter
September 4, 2015
-
Japan Drug Makers See Rising Overseas Sales Ratios in April-June
August 11, 2015
-
IFN-Free Drugs Upending Hepatitis C Market Landscape
July 17, 2015
-
3 Major Japan Makers Shed 1,300 Jobs amid Redundancy Programs
June 30, 2015
-
“80% Generic” Era Would Further Accelerate Contraction of Market for Long-Listed Drugs
June 29, 2015
-
Top-4 Japanese Drug Makers Report Widely Different Financial Results for FY2014
May 22, 2015
-
Will 5,000 Contract Sales Reps Be Just a Way Station for a Higher Goal Beyond?
April 24, 2015
-
Global Drug Sales Rose 8.8% to US$936.5 Billion in 2014: IMS Health
April 3, 2015
-
Development Tie-Ups with Immune Checkpoint Inhibitors Increase; to Maximize Value through Combination
March 27, 2015
-
Most Global Products on Track to Clear Their FY2014 Sales Forecasts; Abilify Posting Sales of 650 Billion Yen
March 16, 2015
-
Will SGLT-2 Inhibitors Catch On? Breakout Will Require Accumulation of Data
February 25, 2015
-
Chugai Aims to Surpass 200 Billion Yen in Its Domestic Oncology Sales in 2015
February 13, 2015
-
EFPIA Predicts Growth in Ethical Drug Market to Just 10 Trillion Yen in 2025
February 6, 2015
-
Edoxaban Approved in US with Restriction on Use; Impact on Daiichi Sankyo’s Midterm Business Plan Remains Unclear
January 30, 2015
-
Pneumococcal Vaccine Market Expanding with Inclusion in Publicly-Funded Vaccination Programs
January 16, 2015
-
Drug Makers Continue Trial and Error Efforts to Improve Lecture Meetings
January 9, 2015
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…